Sudeep Pharma continued its impressive start on Friday, surging nearly 29% above its initial public offering (IPO) price of Rs 593. This upward trend reflects sustained investor trust in the specialized pharmaceutical ingredients producer. The stock debuted at Rs 733.95 on the Bombay Stock Exchange (BSE) and Rs 730 on the National Stock Exchange (NSE), maintaining strong momentum throughout the trading session.
By midday, the company’s shares were trading at Rs 762.05 on the BSE, marking a 28.51% increase from its IPO price. The successful listing was expected following the overwhelming demand seen during the Rs 895 crore IPO, which was oversubscribed 93.72 times, with total bids exceeding Rs 58,700 crore. Even in the unlisted market, the stock traded at a premium of over 20% before its listing, indicating significant interest from early investors.
Prior to the IPO subscription period, Sudeep Pharma secured Rs 268.5 crore from anchor investors. Analysts attribute the positive market response to the company’s robust business model and strategic positioning in the industry. As a prominent supplier of excipients and specialty ingredients for pharmaceuticals, nutraceuticals, and fortified foods, Sudeep Pharma benefits from its strong export presence, diverse mineral-based product portfolio, and established relationships with global pharmaceutical firms.
Dr. Ravi Singh, Chief Research Officer at Master Capital Services Ltd, emphasized the broad-based trust in the company’s fundamentals, driven by solid institutional interest in its focused offerings. While acknowledging the sector’s growth potential due to increasing global demand and India’s expanding role in pharmaceutical supply chains, he warned of potential pricing pressures and trade uncertainties affecting market sentiment.
Shivani Nyati, Head of Wealth at Swastika Investmart Ltd, highlighted the compelling long-term prospects of Sudeep Pharma but advised investors to exercise caution following the substantial listing gain. She suggested that investors who received shares during the IPO might consider booking partial profits and recommended holding the remaining portion with a strict stop-loss at Rs 690 for those interested in the specialty pharmaceutical ingredients sector.
Experts agree that while Sudeep Pharma benefits from favorable industry trends and a scalable business model, its post-listing valuations now require consistent earnings growth and margin stability. The company’s performance in the upcoming quarters will be crucial in justifying the premium bestowed upon it by the market.